Abstract
The goal of this chapter is to offer a brief description of the main characteristics and lessons coming from the main randomized controlled trials, which were considered for inclusion in this chapter if thrombolysis by peripheral vein was evaluated as intervention and had a comparator group including low-molecular-weight heparin, fondaparinux, K-vitamin antagonists, or unfractionated heparin. In addition, mortality has to be considered (Chatterjee et al., JAMA 311:2414–2421, 2014). Full references are included if the reader wants to deepen the characteristics and results of the randomized control trials.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Konstantinides S, Torbicki A. Management of venous thromboembolism: an update. Eur Heart J. 2014;35:2855–63.
Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost. 2013;39:452–8.
Konstantinides S, Goldhaber SZ. Pulmonary embolism: risk assessment and management. Eur Heart J. 2012;33:3014–22.
Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, Kumbhani DJ, Mukherjee D, Jaff MR, Giri J. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311:2414–21.
The Urokinase Pulmonary Embolism Trial. Urokinase pulmonary embolism trial: phase 1 results: a cooperative study. JAMA. 1970;214:2163–72.
Tibbutt DA, Davies JA, Anderson JA, Fletcher EWL, Hamill J, Holt JM, Thomas ML, Lee G, Miller GAH, Sharp AA, Sutton GC. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J. 1974;1:343–7.
Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand. 1978;203:465–70.
Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration. 1988;54:162–73.
Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98:1473–9.
PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study by the PIOPED Investigators. Chest. 1990;97:528–33.
Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, Zonzin P, Zanuttini D, Barbaresi F, Agnelli G, Morpurgo M, Marini MG, Visani L. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol. 1992;20:520–6.
Goldhaber SZ, Come PC, Lee RT, Braunwald E, Parker JA, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, da Silva AM T, Mogtader A, McDonough TJ. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507–11.
Jerjes-Sanchez C, Ramirez-Rivera A, Garcia ML, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, Rosas E. Streptokinase and heparin vs heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2:227–9.
Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Management strategies and prognosis of pulmonary embolism-3 trial investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143–50.
Becattini C, Agnelli G, Salvi A, Grifoni S, Pancladi LG, Enea I, Blasemin F, Campanini M, Ghirarduzzi A, Casazza F, TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125:e82–6.
Lankeit M, Konstantinides S. Tenecteplase can be given to patients with intermediate-risk pulmonary embolism—but should it? Thromb Res. 2010;126:e407–8.
Fasullo S, Scalzo S, Maringhini G, Ganci F, Canizzaro S, Basile I, Cangemi D, Terrazzino G, Parrinello G, Sarullo FM, Baglini R, Paterna S, Di Pascuale P. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011;341:33–9.
Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M, for the “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol. 2013;111:273–7.
Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Granca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV, PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402–11.
Paul W, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F, for the STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2014;368:1379–87.
Elliot CG. Fibrinolysis of pulmonary emboli–steer closer to Scylla. N Engl J Med. 2014;370:1457–8.
Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Hernandez J. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12:459–68.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jerjes-Sánchez, C., Ramirez-Rivera, A. (2015). Thrombolytic Therapy: Evidence-Based Results from Multicenter Control Trials. In: Thrombolysis in Pulmonary Embolism. Springer, Cham. https://doi.org/10.1007/978-3-319-19707-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-19707-4_3
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-19706-7
Online ISBN: 978-3-319-19707-4
eBook Packages: MedicineMedicine (R0)